Accelerated Approval Legislation Picking Up Speed; ULTRA Becoming FAST
This article was originally published in The Pink Sheet Daily
Executive Summary
Revisions to the House bill make it nearly identical to sections of Sen. Kay Hagan’s legislation. The debate on PDUFA add-ons will be rejoined at a Commerce Committee hearing, but TREAT now has considerable momentum.
You may also be interested in...
Supply Chain Safety’s Dual Visions: Pedigree Or Just Serialization
As Congress considers how to ensure downstream supply chain security, industry groups are looking at a process to link drugs to their manufacturer. But in a recent communication with the Senate HELP Committee, FDA backs a “comprehensive national track-and-trace system.”
TREAT Act Wants Accelerated Approval Change, But Uses Existing Language
Anticipated legislation from Sen. Kay Hagan would copy federal regulations outlining accelerated approval to Food, Drug and Cosmetic Act, also encourage use of more broadly effective processes for expedited reviews.
Accelerated Approval Expansion Proposals Pending, But One Needs An Overhaul
ULTRA bill will need changes to gain the support of influential patient group. Meanwhile, BIO is circulating a proposal to make changes to existing regulations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: